+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Artemisinin Combination Therapy Market by Type, Application, Distribution Channel, Patient Age Group, Formulation, Therapy Type - Global Forecast 2025-2030- Product Image
Artemisinin Combination Therapy Market by Type, Application, Distribution Channel, Patient Age Group, Formulation, Therapy Type - Global Forecast 2025-2030- Product Image
Sale

Artemisinin Combination Therapy Market by Type, Application, Distribution Channel, Patient Age Group, Formulation, Therapy Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6013910
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Artemisinin Combination Therapy Market grew from USD 341.18 million in 2023 to USD 362.34 million in 2024. It is expected to continue growing at a CAGR of 6.46%, reaching USD 529.04 million by 2030.

Artemisinin Combination Therapy (ACT) is a pivotal development in malaria treatment, integrating artemisinin derivatives with other antimalarial drugs to improve efficacy and tackle drug resistance. The necessity of ACT arises from its ability to rapidly reduce the parasite biomass in the human body, offering an effective remedy to malaria, especially in areas plagued with Plasmodium falciparum strains that show resistance to older medications. This treatment's application is predominantly in endemic regions across Africa, Asia, and parts of South America, where it addresses the pressing need to combat rising malaria cases. The end-use scope of ACT is widespread, covering hospitals, clinics, and designated malaria treatment centers. Market growth is stimulated by several factors, including international health campaigns, increased funding, and the urgent need for novel, efficacious treatments as resistance to older drugs escalates. However, key challenges such as the high cost of ACT production, counterfeit drugs, and inconsistent adherence to treatment guidelines pose significant barriers. Moreover, varying regulatory protocols and limited healthcare infrastructure in low-income regions further impede market expansion. Emerging opportunities for growth are present in technological advancements that streamline ACT production and distribution, and increased partnerships between governments and pharmaceutical companies to enhance drug accessibility. Firms should explore research innovations that focus on developing cost-effective synthesis of artemisinin, as well as enhanced drug formulations with prolonged efficacy. Another promising area is the exploration of combination therapies that incorporate novel drugs or diagnostic tools for rapid detection and treatment customization. The market exhibits a dynamic nature, shaped by evolving malarial patterns and resistance trajectories, demanding continuous innovation and adaptation to sustain market leadership and fully leverage potential opportunities.

Understanding Market Dynamics in the Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing prevalence of malaria leading to increased demand for artemisinin combination therapy
    • Government initiatives promoting the use of artemisinin combination treatments
    • Rising awareness about the advantages of combination therapy for malaria treatment
  • Market Restraints
    • High production costs and supply chain inefficiencies
  • Market Opportunities
    • Heightened government and private sector investments in antimalarial drug research
    • Rising collaborations and partnerships between pharmaceutical companies and research institutes
  • Market Challenges
    • Regulatory hurdles related to the global distribution of artemisinin combination therapy

Exploring Porter’s Five Forces for the Artemisinin Combination Therapy Market

Porter’s Five Forces framework further strengthens the insights of the Artemisinin Combination Therapy Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Artemisinin Combination Therapy Market

External macro-environmental factors deeply influence the performance of the Artemisinin Combination Therapy Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Artemisinin Combination Therapy Market, highlighting leading vendors and their innovative profiles. These include Ajanta Pharma Limited, Aurobindo Pharma Limited, Cipla Limited, Dafra Pharma International NV, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Guilin Pharmaceutical Co., Ltd., Ipca Laboratories Limited, KPC Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis International AG, Pfizer Inc., Ranbaxy Laboratories Limited, Sanofi S.A., Shin Poong Pharmaceutical Co., Ltd., Strides Pharma Science Limited, Sumaya Biotech Pvt. Ltd., Turing Pharmaceuticals AG, and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Artemisinin Combination Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Artemether-Lumefantrine
    • Artesunate-Amodiaquine
    • Artesunate-Mefloquine
    • Artesunate-Pyronaridine
    • Dihydroartemisinin-Piperaquine
  • Application
    • Clinic
    • Hospital
    • Household
    • Research Institute
  • Distribution Channel
    • Drug Stores
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Patient Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Formulation
    • Capsule
    • Injection
    • Suspension
    • Tablet
  • Therapy Type
    • Combination Therapy
    • First-Line Therapy
    • Mono Therapy
    • Second-Line Therapy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of malaria leading to increased demand for artemisinin combination therapy
5.1.1.2. Government initiatives promoting the use of artemisinin combination treatments
5.1.1.3. Rising awareness about the advantages of combination therapy for malaria treatment
5.1.2. Restraints
5.1.2.1. High production costs and supply chain inefficiencies
5.1.3. Opportunities
5.1.3.1. Heightened government and private sector investments in antimalarial drug research
5.1.3.2. Rising collaborations and partnerships between pharmaceutical companies and research institutes
5.1.4. Challenges
5.1.4.1. Regulatory hurdles related to the global distribution of artemisinin combination therapy
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Artemisinin Combination Therapy Market, by Type
6.1. Introduction
6.2. Artemether-Lumefantrine
6.3. Artesunate-Amodiaquine
6.4. Artesunate-Mefloquine
6.5. Artesunate-Pyronaridine
6.6. Dihydroartemisinin-Piperaquine
7. Artemisinin Combination Therapy Market, by Application
7.1. Introduction
7.2. Clinic
7.3. Hospital
7.4. Household
7.5. Research Institute
8. Artemisinin Combination Therapy Market, by Distribution Channel
8.1. Introduction
8.2. Drug Stores
8.3. Hospital Pharmacies
8.4. Online Pharmacies
8.5. Retail Pharmacies
9. Artemisinin Combination Therapy Market, by Patient Age Group
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Artemisinin Combination Therapy Market, by Formulation
10.1. Introduction
10.2. Capsule
10.3. Injection
10.4. Suspension
10.5. Tablet
11. Artemisinin Combination Therapy Market, by Therapy Type
11.1. Introduction
11.2. Combination Therapy
11.3. First-Line Therapy
11.4. Mono Therapy
11.5. Second-Line Therapy
12. Americas Artemisinin Combination Therapy Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Artemisinin Combination Therapy Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Artemisinin Combination Therapy Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ARTEMISININ COMBINATION THERAPY MARKET RESEARCH PROCESS
FIGURE 2. ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
FIGURE 17. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 21. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ARTEMISININ COMBINATION THERAPY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 27. ARTEMISININ COMBINATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ARTEMISININ COMBINATION THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ARTEMISININ COMBINATION THERAPY MARKET DYNAMICS
TABLE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTEMETHER-LUMEFANTRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE-AMODIAQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE-MEFLOQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE-PYRONARIDINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DIHYDROARTEMISININ-PIPERAQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOUSEHOLD, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY MONO THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 60. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 61. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 66. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 88. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 93. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 94. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 98. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 99. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 106. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 110. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 111. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 116. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 117. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 122. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 123. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 129. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 134. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 135. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 141. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 142. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 146. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 147. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 153. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 161. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 162. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 165. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 166. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 167. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 168. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 171. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 172. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 173. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 174. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 177. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 178. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 179. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 183. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 184. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 185. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 186. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 190. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 196. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 197. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 198. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 201. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 202. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 215. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 216. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 219. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 220. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 221. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 222. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 226. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 227. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 228. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 232. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 251. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 252. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 255. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 256. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 262. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 268. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 269. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 270. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 273. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 274. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 286. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 287. ARTEMISININ COMBINATION THERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 288. ARTEMISININ COMBINATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Artemisinin Combination Therapy market, which are profiled in this report, include:
  • Ajanta Pharma Limited
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dafra Pharma International NV
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Guilin Pharmaceutical Co., Ltd.
  • Ipca Laboratories Limited
  • KPC Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Pfizer Inc.
  • Ranbaxy Laboratories Limited
  • Sanofi S.A.
  • Shin Poong Pharmaceutical Co., Ltd.
  • Strides Pharma Science Limited
  • Sumaya Biotech Pvt. Ltd.
  • Turing Pharmaceuticals AG
  • Zydus Cadila

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 362.34 Million
Forecasted Market Value ( USD ) by 2030 $ 529.04 Million
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Artemisinin Combination Therapy Market Size, Share and Trends Analysis Report by Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), and Region 2024-2030 - Product Image

Artemisinin Combination Therapy Market Size, Share and Trends Analysis Report by Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), and Region 2024-2030

  • Report
  • 100 Pages
  • Global
From
Artemisinin Combination Therapy Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030 - Product Image

Artemisinin Combination Therapy Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

  • Report
  • 180 Pages
  • Global
From
Artemisinin Combination Therapy Market - Growth, Trends, and Forecasts (2023 - 2028) - Product Image

Artemisinin Combination Therapy Market - Growth, Trends, and Forecasts (2023 - 2028)

  • Report
  • 111 Pages
  • Global
From
United States Artemisinin Combination Therapy Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2030 - Product Image

United States Artemisinin Combination Therapy Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2030

  • Report
  • 80 Pages
  • United States
From
Vietnam Artemisinin Combination Therapy Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2030 - Product Image

Vietnam Artemisinin Combination Therapy Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2030

  • Report
  • 80 Pages
  • Vietnam
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.